Advantage Alpha Capital Partners LP Fennec Pharmaceuticals Inc. Call Options Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.9MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$24.4 Million0.57% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$14.4 Million27.51% of portfolio
-
Solas Capital Management, LLC Darien, CT1.92MShares$11.5 Million7.68% of portfolio
-
Dg Capital Management, LLC New York, NY1.52MShares$9.12 Million4.41% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.11 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $156M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...